Treatment Options for Patients With Chronic Graft vs Host Disease

Comparing 1-Year OS and RFS in Patients Treated With ABA in Combination With a CNI/MTX vs ATG or PT-Cy Following Allogenic HCT

Impact of GVHD Prophylaxis on CMV Reactivation and Disease After HLA-Matched Peripheral Blood Stem Cell Transplantation

The Clinical Impact of Donor Against Recipient HLA One Way Mismatch on the Occurrence of Graft versus Host Disease in Liver Transplantation

A Phase 1 Study of Donor Regulatory T-Cell Infusion Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD

Novel Haploidentical Bone Marrow Transplantation Approach Effective in Relapsed/Refractory Severe Aplastic Anemia

Improving Patient Access to Therapies for Chronic Graft vs Host Disease

Understanding Symptom Burden, Disease Severity in Graft vs Host Disease

Treatment Options for Patients With Chronic Graft vs Host Disease

header-info

Sep, 19, 2022

Meilin Diaz-Paez, MSN, APRN, FNP-BC, AOCNP, BMTCN, advanced practice registered nurse, Division of Transplantation & Cellular Therapy, University of Miami Sylvester Comprehensive Cancer Center, walks through available therapies for patients with chronic graft vs host disease with a focus on how belumosudil fits into the treatment paradigm.

This interview is part of the series, "Current Treatments and Unmet Need in Chronic Graft vs Host Disease."